Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
QDrkcZkxBZedey4A
